VXRT Vaxart

Vaxart, Inc. to Participate in September Virtual Investor Conferences

Vaxart, Inc. to Participate in September Virtual Investor Conferences

- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th – 16th

- Sachs Associates: 20th Annual Biotech in Europe Forum - September 21st – 24th

- SVB Leerink: CybeRx Series: Vaccine Forum - September 23rd & – 24th

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced senior management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

H.C. Wainwright: 22nd Annual Global Investment Conference

Title:Vaxart, Inc. (VXRT) Company Presentation / Fireside Chat
Date:Monday, September 14th 2020
Time:10:30 am Eastern Time
Presenter:Andrei Floroiu, President & CEO
  
Sachs Associates: 20th Annual Biotech in Europe Forum
Title (1):Pandemic Response Day: Vaccine Panel
Date:Monday, September 21st 2020
Time:13:05 -14:00 Central European Time
Panelists:Andrei Floroiu, President & CEO Vaxart, Inc.

 Andrew Allen, Co-Founder, President & CEO, Gritstone Oncology
 Frederic Ors, CEO, IMV, Inc.
 Johan Van Hoof, Global Therapeutic Area Head, IDV Vaccines, Johnson & Johnson
  
Title (2):Spotlight Showcase Vaxart, Inc. (VXRT) Company Presentation
Date:Monday, September 21st 2020
Time:14:05 -14:25 Central European Time
Presenter:Andrei Floroiu, President & CEO Vaxart, Inc.
  
SVB LEERINK: CybeRx Series – Vaccine Forum
Title:Vaxart, Inc. (VXRT) - Fireside Chat
Date:Wednesday, September 23rd 2020
Time:2:00 am Eastern Time
Presenters:Andrei Floroiu, President & CEO
 Sean Tucker, Ph.D., Founder & Chief Scientific Officer

Webcast Links

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Company’s website.

About Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet vaccine is easier to distribute, store and administer than injectable vaccines and may provide significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit

Contacts

Investors:

Joyce Allaire

LifeSci Advisors



617.435.6602

Media:

Gloria Gasaatura

LifeSci Communications



646.970.4688

EN
03/09/2020

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart Provides Business Update and Reports Third Quarter 2025 Financi...

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus va...

November 13, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Upcoming Conference Calls

Vaxart to Host Upcoming Conference Calls Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today announced it will host two upcoming webcast conference calls. Third Quarter 2025 Financial ResultsVaxart will provide a business update and report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 13, 2025. The Vaxart senior mana...

November 7, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Va...

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025 SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research featuring its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 taking place October 19-22, 2025, at the Georgia World Congress Center in Atlanta. IDWeek Oral Abstract Presentation: Presen...

October 20, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candid...

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025. Vaxart’s mission is to ...

October 8, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

Vaxart Announces Withdrawal of Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has withdrawn its reverse stock split proposal. “After careful consideration, we have decided to officially withdraw our reverse stock split proposal. Moving forward, we will continue to communicate frequently with our stockholders across multiple channels...

September 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch